Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese IP reforms promise boost to trade and competitiveness:

This article was originally published in Clinica

Executive Summary

An overhaul of China's intellectual property (IP) regime promises to boost local enterprise and international co-operation alike, according to the government. The "China 2008 IP Rights Protection Action Plan", which was unveiled in basic terms last week by the State IP Office, features 280 amendments in 10 key areas. These include: IP protection for local enterprises, featuring guidance on developing IP systems and on how best to use them to improve competitiveness; international co-operation, with 27 measures that include encouraging inspection trips and seminars; revised and new legislation, affecting foreign trade, among other areas; improvements to processes, seeking increased co-ordination between central government and the regions, and better complaint and reporting systems; publicity; training; and IP-related research.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046655

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel